 |
|
|
|
DAKTARIN oral gel contains the active ingredient miconazole. Miconazole is an antifungal medicine used to treat infections with fungi and yeasts.
Miconazole kills fungi and yeasts by interfering with their cell membranes. It works by stopping the fungi from producing a substance called ergosterol, which is an essential component of fungal cell membranes. The disruption in production of ergosterol disrupts the fungal cell membrane, causing holes to appear in it.
The cell membranes of fungi are vital for their survival. They keep unwanted substances from entering the cells and stop the contents of the cells from leaking out. As miconazole causes holes to appear in the cell membranes, essential constituents of the fungal cells can leak out. This kills the fungi and treats the infection.
Miconazole also has some antibacterial action and kills certain bacteria that may also be present in the infection.
DAKTARIN oral gel is used to treat fungal infections of the mouth and throat, such as oral thrush. For treating localised areas of infection in the mouth, a small amount of gel may be applied directly to the affected area with a clean finger. Daktarin oral gel is also used to treat fungal infections of the intestines.
The gel should be held in the mouth for as long as possible before swallowing.
Product information leaflet:
http://emc.medicines.org.uk/medicine/7301/SPC/Daktarin Oral Gel/
|
|
Each gram of Daktarin Oral Gel contains 20 mg of miconazole.
Oral gel.
White gel with orange taste.
|
|
Oral treatment and prevention of fungal infections of the oropharynx and of superinfections due to Gram-positive bacteria.
For localised lesions of the mouth, a small amount of gel may be applied directly to the affected area with a clean finger.
For topical treatment of the oropharynx, the gel should be kept in the mouth for as long as possible.
Treatment should be continued for up to 2 days after the symptoms have cleared.
For oral candidosis, dental prostheses should be removed at night and brushed with the gel.
|
|
Known hypersensitivity to miconazole or to any of the excipients.
In infants less than 4 months of age or in those whose swallowing reflex is not yet sufficiently developed.
In patients with liver dysfunction.
Coadministration of the following drugs that are subject to metabolism by CYP3A4: (See Section 4.5 Interactions with Other Medicinal Products and Other Forms of Interaction)
- Substrates known to prolong the QT-interval e.g., astemizole, cisapride, dofetilide, mizolastine, pimozide, quinidine, sertindole and terfenadine
- Ergot alkaloids
- HMG-CoA reductase inhibitors such as simvastatin and lovastatin
- Triazolam and oral midazolam
|
|
|
